Evidence Comparison
CagriSema and zenagamtide both combine GLP-1 and amylin biology, but they are not the same product concept. CagriSema is a fixed-dose two-component combination under FDA review, while zenagamtide is a single dual-agonist molecule being developed in injectable and oral forms.
Metabolic Combination
Investigational
Phase 3 investigational
Fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.
CagriSema has regulatory-grade-scale Phase 3 evidence, but it remains an investigational fixed-dose combination and should not be treated as a generic DIY cagrilintide-plus-semaglutide blend.
Open CagriSema evidence guide →Metabolic & Weight Loss
Investigational
Phase 3 investigational
Unimolecular peptide agonist of GLP-1 and amylin receptors, under development in both subcutaneous and oral formulations.
Zenagamtide is one molecule targeting GLP-1 and amylin receptors, which makes it mechanistically different from the two-component CagriSema combination even though the pathway pair overlaps.
Open metabolic pipeline record →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.